Rasagiline (Azilect) is one of the important medications currently used for the treatment of Parkinson's disease. As a monoamine oxidase (MAO) inhibitor, this drug carries specific risks such as hypertensive crisis, serotonin syndrome, and daytime somnolence during use, so a systematic medication monitoring system must be established.
Precautions for Using Rasagiline (Azilect)
Risk of Hypertension
Rasagiline may exacerbate hypertension and can induce severe hypertensive syndrome even at the recommended dosage.
When used as adjunctive therapy with levodopa, the incidence of significant blood pressure elevation (systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg) in the 1 mg daily dosage group reaches 4%.
When consuming foods containing extremely high amounts of tyramine (exceeding 150 mg), even the recommended dosage of rasagiline may lead to severe hypertension due to increased tyramine sensitivity.
Sudden Onset of Sleep During Daytime Activities
Some patients may experience sudden sleep onset during routine activities (including driving a vehicle), and some patients have no prior warning symptoms.
Individualized Dosage Regimen
Monotherapy: The recommended dosage is 1 mg once daily.
Adjunctive therapy (without levodopa use): 1 mg once daily.
Adjunctive therapy with levodopa: The initial dosage is 0.5 mg once daily, which can be increased to 1 mg once daily based on clinical needs.
Dosage Adjustments for Special Populations
Patients using CYP1A2 inhibitors: The dosage should not exceed 0.5 mg once daily.
Patients with mild hepatic impairment: The dosage should not exceed 0.5 mg once daily.
Patients with moderate to severe hepatic impairment: Use is contraindicated.
Medication Monitoring for Rasagiline (Azilect)
Standards for Blood Pressure Monitoring
Baseline assessment: Before the start of treatment.
Treatment-phase monitoring: Regularly check for changes in blood pressure.
Symptom monitoring: Closely observe clinical manifestations related to hypertension.
Monitoring of Neurological Symptoms
Hallucinations and psychotic-like behaviors.
Impulse control/compulsive behaviors.
Degree of daytime somnolence.
Absolutely Contraindicated Medications
Meperidine, tramadol, methadone, propoxyphene.
Dextromethorphan.
St. John's wort, cyclobenzaprine.
Other MAO inhibitors.
Key Monitoring Items
Liver function indicators: Special attention should be paid to patients with hepatic impairment.
Hematological tests: Monitor indicators related to anemia.
Mental status assessment: Regularly evaluate changes in cognitive function.
Guidance for Daily Life
Warning regarding driving safety.
Risk reminder for working at heights.
Precautions for operating machinery.
